We strongly oppose the requested extension of the deadline for premarket tobacco product applications (PMTAs), and we urge the FDA to not grant this requested extension.
Read More »Nicotine & Tobacco
NCHR’s Comments on FDA’s Notice on the Modified Risk Tobacco Product Applications for IQOS System With Marlboro Heatsticks
February 24, 2020. We oppose the modified labeling of Marlboro Heatsticks. This change may lead non-smokers, particularly adolescents, to begin using tobacco products.
Read More »Coalition Letter Urging Support for the Reversing the Youth Tobacco Epidemic Act
February 4, 2020 See PDF: Coalition Letter Urging Support for HR 2339 2.4.20 (1) U.S. House of Representatives Washington, DC 20515 Dear Representative: We are writing to express our strong support for H.R. 2339, the Reversing the Youth Tobacco Epidemic Act of 2019. This legislation will address the current youth e-cigarette epidemic that is undermining […]
Read More »NCHR Comments on FDA’s Notice on the Modified Risk Tobacco Product Application for Copenhagen Snuff Fine Cut
January 21, 2020. We strongly oppose the approval of the modified risk application for Copenhagen Snuff Fine Cut with the claim “IF YOU SMOKE, CONSIDER THIS: Switching completely to this product from cigarettes reduces risk of lung cancer.” This claim may encourage non-smokers to begin using tobacco. Using smokeless tobacco increases the risk of serious health issues.
Read More »NCHR’s Comments on FDA’s Proposed Rule on Tobacco Product Applications
December 16, 2019. FDA’s proposed requirements for premarket tobacco product applications (PMTAs) defines the extent to which FDA is able to thoroughly evaluate the potential health effects of these products on consumers and, in particular, vulnerable populations such as children and adolescents.
Read More »